Amotz Nechushtan
Keine laufenden Positionen mehr
Profil
Amotz Nechushtan was the founder of Iluten Ltd.
established in 2010, where he served as the Chief Executive Officer from 2010 to 2013.
He held the position of Vice President-Research & Development at PharmaSeed Ltd., QuantomiX Ltd., and Target-In Ltd.
from 2001 to 2004.
He also served as the Vice President-Research & Development at Cellect Biotechnology Ltd.
from 2016 to 2018.
Dr. Nechushtan holds a doctorate degree from The Hebrew University of Jerusalem.
Ehemalige bekannte Positionen von Amotz Nechushtan
Unternehmen | Position | Ende |
---|---|---|
QUOIN PHARMACEUTICALS, LTD. | Technik-/Wissenschafts-/F&E-Leiter | 01.04.2018 |
Iluten Ltd.
Iluten Ltd. Pharmaceuticals: MajorHealth Technology Iluten Ltd. developed a novel anti-inflammatory drug for the treatment of inflammatory bowel disease. It was established under a strategic collaboration between Pontifax and Clal Biotechnology. The new drug, a monoclonal antibody that modulates the immune system, has shown promising good results both in vitro and in vivo (in IBD and Multiple sclerosis animal disease models). The company was founded by Dr. Amotz Nechushtan in 2010 and is headquartered in Ashkelon, Israel. | Vorstandsvorsitzender | 01.01.2013 |
Target-In Ltd. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2004 |
PharmaSeed Ltd. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2004 |
QuantomiX Ltd.
QuantomiX Ltd. Pharmaceuticals: MajorHealth Technology QuantomiX Ltd. develops and markets capsules that enable real-time analysis of wet cells and tissue biopsies. The firm with the its QXTM capsule product line, wet samples, including cells and tissues biopsies, will be able to be examined immediately and accurately. The company's technology enables scanning electron microscopes (SEM) to image and analyze wet samples such as cells, tissue biopsies, foods and ink, in their native environment. QuantomiX was founded in March 2001 by Micha Brunstein, Zachy Berger and Ory S. Zik and is headquartered in Rehovot, Israel. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2004 |
Ausbildung von Amotz Nechushtan
The Hebrew University of Jerusalem | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
QuantomiX Ltd.
QuantomiX Ltd. Pharmaceuticals: MajorHealth Technology QuantomiX Ltd. develops and markets capsules that enable real-time analysis of wet cells and tissue biopsies. The firm with the its QXTM capsule product line, wet samples, including cells and tissues biopsies, will be able to be examined immediately and accurately. The company's technology enables scanning electron microscopes (SEM) to image and analyze wet samples such as cells, tissue biopsies, foods and ink, in their native environment. QuantomiX was founded in March 2001 by Micha Brunstein, Zachy Berger and Ory S. Zik and is headquartered in Rehovot, Israel. | Health Technology |
Cellect Biotechnology Ltd.
Cellect Biotechnology Ltd. Medical SpecialtiesHealth Technology Cellect Biotechnology Ltd. engages in the provision of regenerative medicine. Its activities include development of regenerative medicine through the development of products facilitating immune stem cell selection. The company also develops innovative technology, which allows the default stem cells by dramatically reducing of complications existing in conventional selection methods. The company was founded by Kasbian Nuriel Chirich, Shai Yarkoni, and Nadir Askenasy on August 4, 1986 and is headquartered in Kfar Saba, Israel. | Health Technology |
PharmaSeed Ltd. | |
Iluten Ltd.
Iluten Ltd. Pharmaceuticals: MajorHealth Technology Iluten Ltd. developed a novel anti-inflammatory drug for the treatment of inflammatory bowel disease. It was established under a strategic collaboration between Pontifax and Clal Biotechnology. The new drug, a monoclonal antibody that modulates the immune system, has shown promising good results both in vitro and in vivo (in IBD and Multiple sclerosis animal disease models). The company was founded by Dr. Amotz Nechushtan in 2010 and is headquartered in Ashkelon, Israel. | Health Technology |
Target-In Ltd. |